Skip to content

A Cohort Study on Cardiovascular Prognosis and Intervention Efficacy Prediction in Hemodialysis Patients Based on the Novel PEW Model

A Cohort Study on Cardiovascular Prognosis and Intervention Efficacy Prediction in Hemodialysis Patients Based on the Novel PEW Model

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600127610
Enrollment
Unknown
Registered
2026-07-02
Start date
2026-01-03
Completion date
Unknown
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal failure,hemodialysis

Interventions

Low-Risk Group (LPEW):None
High-Risk Group (HPEW):None

Sponsors

Shanghai East Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Regular hemodialysis for more than 3 months; 2. Age between 18 and 80 years; 3. If complicated with cardiovascular disease, able to receive standard antiplatelet therapy, ACEI/ARB, CCB, etc.; 4. Voluntarily sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Acute cardiovascular or cerebrovascular events within 3 months prior to screening; 2. Active infection; 3. Active liver disease or abnormal liver function (ALT or AST > 2.5 times the upper limit of normal) or history of liver cirrhosis; 4. History of cardiac surgery within 3 months prior to screening; 5. Diagnosis of malignancy or ongoing radiotherapy/chemotherapy within 3 months prior to screening; 6. Life-threatening severe infection within 3 months prior to screening; 7. Pregnant or lactating women, or patients on estrogen replacement therapy; 8. Active infectious diseases such as active tuberculosis, HIV infection, etc.; 9. Patients with psychiatric disorders taking psychotropic medications; 10. Patients assessed by the physician as difficult to follow up or with poor compliance, unsuitable for enrollment; 11. Patients unwilling to sign the informed consent form.

Design outcomes

Primary

MeasureTime frame
MACE;Cardiovascular Disease-Related Death;

Secondary

MeasureTime frame
All-Cause Mortality;PEW score;Echocardiographic parameters;Quality of Life Score;Hospitalization;Complete blood count (CBC),Kidney function parameters,Liver function tests (LFTs),Serum lipid parameters,Cardiac failure biomarkers,Inflammatory biomarkers,Dialysis adequacy indices;

Countries

China

Contacts

Public ContactLiu Na

Shanghai East Hospital

naliubrown@163.com+86 18217768587

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 23, 2026